Supplementary Material for: Role of Raf Kinase Inhibitor Protein in Modulating Echinococcal Cyst Fluid-induced Degranulation in Bone Marrow-Derived Mast Cells by figshare admin karger (2628495)

“…In WT BMMCs, surface RKIP protein expression progressively decreased at 1 hour, 2 hours, and 3 hours post-sensitization, corresponding with degranulation progression (p < 0.05). …”

SEAwise Report on improved predictive models of recruitment under different habitat scenarios and incorporating experimental results by Paco Melià (162862)

“…Recruitment of Western Baltic cod and herring showed decreasing reproductive potential as temperature increased.…”

Data Sheet 1_Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study).docx by Alexia Giovanazzi (16816139)

“…At 12 months, the median change in HbA1c levels did not differ significantly between groups. Regarding app usage, data entries decreased significantly from the first quarter to the second quarter but subsequently stabilised (p = 0.001). …”

Data Sheet 2_Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study).docx by Alexia Giovanazzi (16816139)

“…At 12 months, the median change in HbA1c levels did not differ significantly between groups. Regarding app usage, data entries decreased significantly from the first quarter to the second quarter but subsequently stabilised (p = 0.001). …”

Supplementary file 1_Bibliometrics-guided cyberpharmacology and transcriptomics for multidimensional analysis of the antihepatic fibrosis mechanism of kaempferol.docx by Jiali Liu (327739)

“…Pharmacodynamic evaluations, including pathological section analyses, demonstrated that KA effectively mitigated the fibrotic process and decreased collagen deposition. Further corroborated by ELISA experiments, kaempferol exhibited pronounced anti-fibrotic effects, inhibited inflammatory responses, restored liver function indices, and ameliorated the progression of liver fibrosis. …”

Supplementary Material for: Downregulation of Signal Transducer and Activator of Transcription 4 (STAT4) contributes to impaired osteogenic differentiation of human bone marrow ste... by figshare admin karger (2628495)

“…Results: STAT4 expression progressively decreases during the in vitro expansion of hBMSCs, concomitant with the loss of osteogenic differentiation potential. …”

PDLB - Balance Sheet by Nguyen Linh (19516642)

“…The combination of flat / decreasing costs and double-digit asset growth is very favorable for expense leverage.…”

Table 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 8_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 6_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 7_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”